Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

CI Financial Announces Filing and Mailing of Circular for Special Meeting to Approve Plan of Arrangement with Mubadala Capital ...

CI Financial (TSX:CIX:CA) (OTCPK:CIXXF) received an interim order from the Ontario Superior Court of Justice that authorizes, ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

CI Financial receives an interim court order concerning the transaction under which CI shares will be acquired by an ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...